Skip to content

Study · Not a test of the peptide alone · 2026

8 results

Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.

Gonzales-Uribe A, Ruiz-Cortez R, Collantes-Silva N, Olivero L, Agarwal R, Arambulo-Castillo S, Garcia-Geng A, Lyu X, Mendoza-Quispe D, Becerra-Gonzales V, Butrous H

Clinical research in cardiology : official journal of the German Cardiac Society10 Jul 2025Cited by 10 (Europe PMC)

PMID40637782 (opens in a new tab)DOI10.1007/s00392-025-02710-8 (opens in a new tab)PepBankPUB-40637782
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In a pooled analysis of studies in HFpEF (five semaglutide, one tirzepatide), GLP-1 RAs reduced the composite of all-cause mortality and HF hospitalization by 27% (HR 0.73).

    In plain wordsIn people with HFpEF, pooled studies of GLP-1 drugs, mostly semaglutide, found fewer deaths or heart-failure hospital stays.

    Peptide
    Semaglutide
    Outcome
    DecreaseComposite of all-cause mortality and HF hospitalization
    Study

    n = 4,043

    Comparator
    Placebo or other hypoglycemic agents
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    HR
    0.73 ratio
    composite of all-cause mortality and HF hospitalization

    Source sentences

    Summary
    GLP-1 RAs reduced the composite outcome of all-cause mortality and HF hospitalization by 27% (HR 0.73; 95% CI: 0.60-0.90; I2 = 0%).
    2 context sentences
    Summary · context
    Six studies (five RCTs, one cohort) including 4043 patients were analyzed.
    Summary · context
    Five studies evaluated semaglutide and one tirzepatide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In a pooled analysis of studies in HFpEF (five semaglutide, one tirzepatide), GLP-1 RAs reduced the composite of all-cause mortality and HF hospitalization by 27% (HR 0.73).

    In plain wordsIn people with HFpEF, pooled studies of GLP-1 drugs, including one tirzepatide study, found fewer deaths or heart-failure hospital stays.

    Peptide
    Tirzepatide
    Outcome
    DecreaseComposite of all-cause mortality and HF hospitalization
    Study

    n = 4,043

    Comparator
    Placebo or other hypoglycemic agents
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    HR
    0.73 ratio
    composite of all-cause mortality and HF hospitalization

    Source sentences

    Summary
    GLP-1 RAs reduced the composite outcome of all-cause mortality and HF hospitalization by 27% (HR 0.73; 95% CI: 0.60-0.90; I2 = 0%).
    2 context sentences
    Summary · context
    Six studies (five RCTs, one cohort) including 4043 patients were analyzed.
    Summary · context
    Five studies evaluated semaglutide and one tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In a pooled analysis of studies in HFpEF (five semaglutide, one tirzepatide), GLP-1 RAs reduced HF hospitalizations alone (HR 0.57; 95% CI 0.32-1.00).

    In plain wordsIn people with HFpEF, pooled studies of GLP-1 drugs, mostly semaglutide, found fewer heart-failure hospital stays.

    Peptide
    Semaglutide
    Outcome
    DecreaseHF hospitalization
    Study

    n: not reported in source

    Comparator
    Placebo or other hypoglycemic agents
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    HR
    0.57 ratio
    HF hospitalization

    Source sentences

    Summary
    GLP-1 RAs also reduced HF hospitalizations alone (HR 0.57; 95% CI: 0.32-1.00)
    2 context sentences
    Summary · context
    Six studies (five RCTs, one cohort) including 4043 patients were analyzed.
    Summary · context
    Five studies evaluated semaglutide and one tirzepatide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In a pooled analysis of studies in HFpEF (five semaglutide, one tirzepatide), GLP-1 RAs reduced HF hospitalizations alone (HR 0.57; 95% CI 0.32-1.00).

    In plain wordsIn people with HFpEF, pooled studies of GLP-1 drugs, including one tirzepatide study, found fewer heart-failure hospital stays.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHF hospitalization
    Study

    n: not reported in source

    Comparator
    Placebo or other hypoglycemic agents
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    HR
    0.57 ratio
    HF hospitalization

    Source sentences

    Summary
    GLP-1 RAs also reduced HF hospitalizations alone (HR 0.57; 95% CI: 0.32-1.00)
    2 context sentences
    Summary · context
    Six studies (five RCTs, one cohort) including 4043 patients were analyzed.
    Summary · context
    Five studies evaluated semaglutide and one tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  5. 05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In a pooled analysis of studies in HFpEF (five semaglutide, one tirzepatide), GLP-1 RAs had no significant effect on all-cause mortality (HR 0.81; 95% CI 0.58-1.14).

    In plain wordsIn people with HFpEF, pooled studies of GLP-1 drugs, mostly semaglutide, found no clear change in deaths from any cause.

    Peptide
    Semaglutide
    Outcome
    No significant changeAll-cause mortality
    Study

    n: not reported in source

    Comparator
    Placebo or other hypoglycemic agents
    Outcome group
    Mortality · Cardiovascular

    Measurements

    HR
    0.81 ratio
    all-cause mortality

    Source sentences

    Summary
    no significant effect was found on all-cause mortality (HR 0.81; 95% CI: 0.58-1.14).
    2 context sentences
    Summary · context
    Six studies (five RCTs, one cohort) including 4043 patients were analyzed.
    Summary · context
    Five studies evaluated semaglutide and one tirzepatide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In a pooled analysis of studies in HFpEF (five semaglutide, one tirzepatide), GLP-1 RAs had no significant effect on all-cause mortality (HR 0.81; 95% CI 0.58-1.14).

    In plain wordsIn people with HFpEF, pooled studies of GLP-1 drugs, including one tirzepatide study, found no clear change in deaths from any cause.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAll-cause mortality
    Study

    n: not reported in source

    Comparator
    Placebo or other hypoglycemic agents
    Outcome group
    Mortality · Cardiovascular

    Measurements

    HR
    0.81 ratio
    all-cause mortality

    Source sentences

    Summary
    no significant effect was found on all-cause mortality (HR 0.81; 95% CI: 0.58-1.14).
    2 context sentences
    Summary · context
    Six studies (five RCTs, one cohort) including 4043 patients were analyzed.
    Summary · context
    Five studies evaluated semaglutide and one tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  7. 07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In subgroup analyses of studies in HFpEF, benefits of GLP-1 RAs were greater in patients with atrial fibrillation; no effect size is stated.

    In plain wordsIn people with HFpEF, pooled GLP-1 drug results showed larger benefits in people with atrial fibrillation.

    Peptide
    Semaglutide
    Outcome
    Not applicableSubgroup: atrial fibrillation
    Study

    n: not reported in source

    Comparator
    Placebo or other hypoglycemic agents
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Subgroup analyses revealed greater benefits in patients with atrial fibrillation.
    2 context sentences
    Summary · context
    Six studies (five RCTs, one cohort) including 4043 patients were analyzed.
    Summary · context
    Five studies evaluated semaglutide and one tirzepatide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In subgroup analyses of studies in HFpEF, benefits of GLP-1 RAs were greater in patients with atrial fibrillation; no effect size is stated.

    In plain wordsIn people with HFpEF, pooled GLP-1 drug results showed larger benefits in people with atrial fibrillation.

    Peptide
    Tirzepatide
    Outcome
    Not applicableSubgroup: atrial fibrillation
    Study

    n: not reported in source

    Comparator
    Placebo or other hypoglycemic agents
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Subgroup analyses revealed greater benefits in patients with atrial fibrillation.
    2 context sentences
    Summary · context
    Six studies (five RCTs, one cohort) including 4043 patients were analyzed.
    Summary · context
    Five studies evaluated semaglutide and one tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.